Drug safety evaluation of certolizumab pegol

THU0204 The Positive Effect of Stringent Criteria for Purified Protein Derivation (PPD) Skin Test on Patients Treated with Certolizumab Pegol

(2014) J. Vencovsky et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0084 Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol-treated rheumatoid arthritis patients:

(2014) B. Haraoui et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0126 Evaluation of two dosing regimens of certolizumab pegol for maintenance of clinical response in patients with active rheumatoid arthritis: Primary results from doseflex, a phase IIIB study

(2014) D.E. Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0162 Investigation into the binding affinity of certolizumab pegol to fcrn and functional consequences for fcrn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept

(2014) T. Baker et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease

(2012) Uma Mahadevan et al.   Clinical Gastroenterology and Hepatology

New Drug Therapies on the Horizon for IBD

(2012) Clémentine Perrier et al.   DIGESTIVE DISEASES

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

(2012) Paul Rutgeerts et al.   GASTROENTEROLOGY

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol

(2012) Xavier Hébuterne et al.   GUT

Evolution of treatment for rheumatoid arthritis

(2012) K. S. Upchurch et al.   RHEUMATOLOGY

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX

(2012) E. Choy et al.   RHEUMATOLOGY

Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study

(2012) M. E. Weinblatt et al.   RHEUMATOLOGY

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety

(2011) Gert Van Assche et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

(2011) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

The Use of Surrogate Antibodies to Evaluate the Developmental and Reproductive Toxicity Potential of an Anti-TNFα PEGylated Fab′ Monoclonal Antibody

(2011) Ian Wakefield et al.   TOXICOLOGICAL SCIENCES

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Efficacy and safety of certolizumab pegol in an unselected crohnʼs disease population

(2010) Stephan R. Vavricka et al.   INFLAMMATORY BOWEL DISEASES

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

(2009) Paul Emery et al.   ARTHRITIS AND RHEUMATISM

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

(2009) Roger Palframan et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

(2009) Laurent Beaugerie et al.   LANCET

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

(2008) R Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

(2008) E C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease

(2008) Tim Bourne et al.   BIODRUGS

The Impact of PEGylation on Biological Therapies

(2008) Francesco M Veronese et al.   BIODRUGS

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

(2008) William J. Sandborn   GASTROENTEROLOGY

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

(2008) Brian G. Feagan et al.   GASTROENTEROLOGY

Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease

(2008) Murat Toruner et al.   GASTROENTEROLOGY

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2007) M Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES